Severe neurologic complications of immune checkpoint inhibitors: a single-center review.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are a promising class of anticancer drugs associated with immune-related adverse events (IRAEs). In registration studies of selected cancer populations, neurologic IRAEs were rare. Post-marketing experience describing their prevalence in clinical practice continues to be reported.

Methods

A retrospective cohort of patients treated at our institution with ICIs from 2005 to 2017 was identified. Patients with new neurologic ICD codes documented during or after ICI treatment were enrolled. Comprehensive medical record review identified patients with neurologic IRAEs causally linked to ICIs. This study focused on CTCAE grade 2-4 IRAEs.

Results

526 patients were screened; 55 candidate patients were identified; 5 cases met crite

SUBMITTER: Mancone S 

PROVIDER: S-EPMC12751026 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature